Looking Ahead: Integrating Emerging Therapies and Tools in Early-Stage Alzheimer's DiseasePremiere Date: Thursday, October 8, 2020
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, October 8, 2022
|Sharon Cohen, MD, FRCPC (Moderator)
Behavioural Neurologist, Medical Director, and Principal Investigator
Toronto Memory Program
University of Toronto
|Mark Brody, MD, CPI
President, Principal Investigator
Brain Matters Research
Delray Beach, FL
|Pierre N. Tariot, MD
Director, Banner Alzheimer's Institute
Research Professor of Psychiatry
University of Arizona College of Medicine
Alzheimer's disease (AD), a heterogeneous, neurodegenerative condition with an insidious onset and slow progression, is the leading cause of disability and morbidity as well as the sixth-leading cause of death in the United States. Diagnosing AD is often complicated due to its varied clinical symptomatology and unknown etiology, and currently only symptomatic therapies are available.
Recent clinical trials investigating disease-modifying therapies (DMTs) that could slow or reverse the progression of AD have shown great promise. These recent advances in the development of AD therapies have led to the need for health care providers (HCPs) to be knowledgeable about the pathogenesis of AD and its potential implications for treatment, current diagnostic criteria for early recognition, recent advances in the field of imaging in AD, and the latest clinical evidence on emerging DMTs from select patient populations.
This Live and OnDemand webcast will feature interactive and lively discussion among specialists who treat patients with AD, with a focus on recognizing early-stage symptoms of AD, the potential role of emerging therapies in treating patients with early-stage AD, and integrating multimodal imaging strategies into the diagnostic process.
At the end of this CE activity, participants should be able to:
- Recognize the clinical presentation of early-stage AD.
- Assess the safety and efficacy of emerging therapies and their potential role in the treatment continuum of patients with early-stage AD.
- Integrate multimodal imaging and biomarker strategies into the diagnostic process ofAD to inform clinical decision-making.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Recognize the clinical presentation of early-stage AD.
- Discuss the safety and efficacy of emerging therapies and their potential role in the treatment continuum of patients with early-stage AD.
- Summarize how to integrate multimodal imaging and biomarker strategies into the diagnostic process of AD to inform clinical decision-making.
Supported by educational grants from Biogen MA, Inc. and Eisai Inc.
Primary care physicians, neurologists, psychiatrists, geriatricians, nurse practitioners, PAs, nurses and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABPN MOC: ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Cohen reports that she receives research support from AbbVie Inc.; AgeneBio, Inc.; Eisai Co., Ltd.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, USA Inc.; Novartis; and RetiSpec Inc. She is on the advisory committee for Biogen and ProMIS Neurosciences. She is a consultant for Biogen; Black Diamond Therapeutics, Inc.; Cogstate; Eli Lilly and Company; and RetiSpec Inc.
Dr. Brody reports he receives grants from Biogen and Eisai Inc. He is a stockholder (directly purchased) in Biogen.
Dr. Tariot reports that he receives research support from AbbVie Inc.; Avanir Pharmaceuticals, Inc.; Biogen MA, Inc.; Cortexyme; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, USA Inc.; Merck & Co., Inc.; and Novartis. He is on the advisory committee for ACADIA Pharmaceuticals Inc.; Axsome Therapeutics, Inc.; BioXcel Therapeutics, Inc.; Cortexyme; Eisai Co., Ltd.; and Syneos Health. He is a consultant for Astex Pharmaceuticals; eNova; Immune; and Otsuka America Pharmaceutical, Inc. He is a stock shareholder (directly purchased) in Adamas Pharmaceuticals, Inc. He receives other financial support from Alzheimer's Association; Alzheimer's Foundation; Arizona Department of Health Services; Banner Health; Flinn Foundation; FBRI; Geoffrey Beene Foundation; GHR Foundation; National Institute on Aging; and NOMIS Foundation.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Rachel Speer, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).